Atossa Genetics to Present at the 9th Annual LD Micro Main Event Conference on December 7, 2016

SEATTLE, WA--(Marketwired - Dec 1, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that Kyle Guse, CFO and General Counsel, will be a featured presenter at the 9th annual LD Micro Main Event Conference on December 7, 2016 at 12:30pm PST, Track 4, at the Luxe Sunset Hotel in Los Angeles, CA. Management will also be available for one-on-one meetings on December 7 and 8, 2016.

Registered attendees may request meetings through the Meetmax system through the following link: http://www.meetmax.com/sched/event_36847/invitee_login.html.

View Atossa Genetics' Profile here: http://www.ldmicro.com/profile/atos

About LD Micro

The LD Micro Main Event is the largest independent conference for small/microcap companies and will feature 240 presenters. LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

About Atossa Genetics
Atossa Genetics Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.

Forward-Looking Statements
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.